NF-κB1 Regulates Immune Environment and Outcome of Notch-Dependent T-Cell Acute Lymphoblastic Leukemia.
NF-κB1
Notch
T-ALL
Tregs
myeloproliferation
tumor environment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
01
2020
accepted:
10
03
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
27
3
2021
Statut:
epublish
Résumé
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive pediatric malignancy that arises from the transformation of immature T-cell progenitors and has no definitive cure. Notch signaling governs many steps of T cell development and its dysregulation represents the most common causative event in the pathogenesis of T-ALL. The activation of canonical NF-κB pathway has been described as a critical downstream mediator of Notch oncogenic functions, through the sustaining of tumor cell survival and growth. The potential role of Notch/NF-κB partnership is also emerging in the generation and function of regulatory T cells (Tregs) in the context of cancer. However, little is known about the effects of combined mutations of Notch and NF-κB in regulating immune-environment and progression of T-ALL. To shed light on the topics above we generated double-mutant mice, harboring conventional
Identifiants
pubmed: 32346377
doi: 10.3389/fimmu.2020.00541
pmc: PMC7169422
doi:
Substances chimiques
NF-kappa B
0
Receptors, Notch
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
541Informations de copyright
Copyright © 2020 Grazioli, Orlando, Giordano, Noce, Peruzzi, Scafetta, Screpanti and Campese.
Références
Cell. 2017 Sep 7;170(6):1096-1108.e13
pubmed: 28886380
Eur J Immunol. 2010 Mar;40(3):677-81
pubmed: 20082358
J Exp Med. 1999 Jan 4;189(1):145-58
pubmed: 9874571
Leukemia. 2014 Dec;28(12):2324-35
pubmed: 24727676
J Immunol. 2011 Jun 1;186(11):6199-206
pubmed: 21508258
Cell. 1995 Jan 27;80(2):321-30
pubmed: 7834752
Mol Pharmacol. 2004 Mar;65(3):571-81
pubmed: 14978235
Hum Mol Genet. 2016 Mar 1;25(5):903-15
pubmed: 26721932
Front Immunol. 2018 Jul 16;9:1649
pubmed: 30061899
Front Immunol. 2018 Apr 09;9:652
pubmed: 29686671
Cancer Immunol Res. 2014 Aug;2(8):800-11
pubmed: 24830414
Oncogene. 2005 Feb 3;24(6):992-1000
pubmed: 15592506
DNA Repair (Amst). 2016 Jun;42:63-71
pubmed: 27156098
Trends Immunol. 2015 Dec;36(12):802-814
pubmed: 26617322
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3788-93
pubmed: 11891328
J Exp Med. 2009 Dec 21;206(13):3001-14
pubmed: 19995950
J Exp Med. 1996 May 1;183(5):2283-91
pubmed: 8642337
Science. 2004 Oct 8;306(5694):269-71
pubmed: 15472075
Nat Rev Immunol. 2012 Feb 10;12(3):157-67
pubmed: 22322317
Front Immunol. 2018 Oct 11;9:2165
pubmed: 30364244
Oncogene. 2016 Nov 24;35(47):6077-6086
pubmed: 27157619
Oncogene. 2018 Dec;37(49):6285-6298
pubmed: 30038265
Immunity. 2017 Sep 19;47(3):450-465.e5
pubmed: 28889947
Int Immunol. 2009 Jun;21(6):727-43
pubmed: 19461123
Nat Immunol. 2009 Jan;10(1):38-47
pubmed: 19060899
Eur J Immunol. 2016 Jul;46(7):1656-68
pubmed: 27130185
Leukemia. 2015 Jun;29(6):1301-11
pubmed: 25655195
Immunity. 2000 Jul;13(1):73-84
pubmed: 10933396
Curr Mol Med. 2014 Jan;14(1):34-44
pubmed: 24236458
Oncol Lett. 2012 Feb;3(2):421-424
pubmed: 22740924
Cell Cycle. 2007 Nov 15;6(22):2730-4
pubmed: 18032925
Cancer Cell. 2010 Sep 14;18(3):268-81
pubmed: 20832754
Cancer Res. 2016 Mar 15;76(6):1641-52
pubmed: 26801976
Nat Immunol. 2014 Jan;15(1):15-25
pubmed: 24352326
Annu Rev Pathol. 2017 Jan 24;12:245-275
pubmed: 27959635
Blood. 2006 Jul 1;108(1):305-10
pubmed: 16507772
Arthritis Res Ther. 2014 Sep 24;16(5):442
pubmed: 25248297
Nature. 2000 Mar 9;404(6774):193-7
pubmed: 10724173
Mol Cancer Res. 2005 Jun;3(6):345-53
pubmed: 15972853
J Immunol. 2003 Nov 1;171(9):4504-11
pubmed: 14568923
Front Immunol. 2018 Jun 04;9:1288
pubmed: 29915603
Cell Mol Life Sci. 2014 Jun;71(11):2083-102
pubmed: 24419302
J Immunol. 2002 Feb 15;168(4):1738-45
pubmed: 11823505
Haematologica. 2008 Apr;93(4):524-32
pubmed: 18322253
J Immunol. 2009 May 1;182(9):5757-62
pubmed: 19380823
Cancer Res. 2009 Feb 15;69(4):1314-23
pubmed: 19208840
Nat Med. 2007 Jan;13(1):70-7
pubmed: 17173050
Blood. 2014 Apr 17;123(16):2451-9
pubmed: 24608975
J Leukoc Biol. 2017 Aug;102(2):361-368
pubmed: 28292944
EMBO J. 2006 Mar 8;25(5):1000-8
pubmed: 16498412
Oncogene. 2016 Sep 8;35(36):4741-51
pubmed: 26876201
Cancer Cell. 2018 Oct 8;34(4):536-548
pubmed: 30146333
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212
PLoS One. 2008 Jul 02;3(7):e2555
pubmed: 18596915
J Exp Med. 2001 Jul 2;194(1):99-106
pubmed: 11435476
Front Immunol. 2018 Jan 30;9:101
pubmed: 29441071
Nat Rev Mol Cell Biol. 2016 Nov;17(11):722-735
pubmed: 27507209
Oncogene. 2012 Aug 16;31(33):3807-17
pubmed: 22120716
PLoS One. 2017 Oct 12;12(10):e0185762
pubmed: 29023469
Biol Reprod. 2014 Mar 13;90(3):53
pubmed: 24478388
EMBO J. 2000 Jul 3;19(13):3337-48
pubmed: 10880446
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14590-5
pubmed: 9405657
Nat Immunol. 2005 Nov;6(11):1142-51
pubmed: 16227984
Immunity. 2009 Dec 18;31(6):932-40
pubmed: 20064450
J Exp Med. 2003 Apr 7;197(7):861-74
pubmed: 12668645
Semin Immunol. 2003 Apr;15(2):107-12
pubmed: 12681947
Nat Rev Cancer. 2009 Jun;9(6):400-14
pubmed: 19440234